Logo wahanariau.com
  2. Zymeworks

Zymeworks

Index
Globenewswire

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Rabu, 07 Januari 2026 - 06:05:03 Wib
Globenewswire

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Rabu, 19 November 2025 - 03:43:44 Wib
Globenewswire

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Rabu, 19 November 2025 - 03:42:51 Wib
Globenewswire

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Senin, 17 November 2025 - 19:50:43 Wib
Globenewswire

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Sabtu, 25 Oktober 2025 - 02:18:38 Wib
Globenewswire

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Selasa, 14 Oktober 2025 - 20:27:51 Wib
Globenewswire

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Jumat, 10 Oktober 2025 - 03:04:58 Wib
Globenewswire

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Selasa, 02 September 2025 - 23:08:33 Wib
Globenewswire

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Selasa, 12 Agustus 2025 - 04:52:12 Wib
Globenewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Selasa, 29 Juli 2025 - 03:29:52 Wib
Globenewswire

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jumat, 18 Juli 2025 - 01:26:40 Wib
Globenewswire

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Jumat, 30 Mei 2025 - 17:30:00 Wib
Globenewswire

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Jumat, 23 Mei 2025 - 21:25:59 Wib
Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences-.

Kamis, 22 Mei 2025 - 04:17:17 Wib
Globenewswire

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Rabu, 21 Mei 2025 - 02:57:26 Wib
Globenewswire

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Sabtu, 26 April 2025 - 21:57:54 Wib
Globenewswire

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Selasa, 22 April 2025 - 00:54:09 Wib
Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences (March 26, 2025)

Rabu, 26 Maret 2025 - 22:50:07 Wib
Globenewswire

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Rabu, 26 Maret 2025 - 22:32:23 Wib
Globenewswire

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Rabu, 26 Februari 2025 - 23:51:40 Wib
Globenewswire

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Kamis, 13 Februari 2025 - 21:16:56 Wib
Globenewswire

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Kamis, 09 Januari 2025 - 05:00:00 Wib
Globenewswire

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

Kamis, 12 Desember 2024 - 21:00:00 Wib
Globenewswire

Zymeworks Announces Participation in Upcoming Investor Conferences-

Kamis, 21 November 2024 - 18:30:00 Wib
Globenewswire

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Kamis, 21 November 2024 - 18:30:00 Wib